🔗 Share this article

As America proceeds with unprecedented changes to its vaccine recommendations, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by questioning Covid vaccines throughout the global health crisis and has focused upon possible fatalities following COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Program

Public health authorities planned to unveil sweeping changes to the childhood vaccination calendar recently, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of step with a large portion of the global community with no evidence for improved outcomes. The planned update has been postponed until the new year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to head the office this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon rolling back previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric shot schedules in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a citizenry roughly the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has little discernible background in drug development, oversight or leadership, which has been typical for previous leaders of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a large organization. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who ran CBER have had.”

The drug center has an enormous portfolio at the FDA, the former commissioner emphasized.

“Many people just zeroes in on the new drug program, but the generic program authorizes thousands of generic drugs. There’s a biosimilars division, OTC medication office and more, and all of those have to be managed,” Woodcock said. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial administrative component to the position, which manages more than 5,000 employees. “It’s a massive administrative position, if you execute it properly,” she added.

Response and Disputed Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary responded that the “concerns are based on incorrect assumptions”.

“Her experience aligns with the functions of her role,” the official said, citing the period Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial expedited therapy clearance system that allegedly worried her former heads. “By what process are these therapies being picked for this voucher program? Who takes the choices?” Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

In general, he remarked, “the agency seems to be moving towards laxer oversight of all drugs, aside from immunizations.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, past, critics observe. She published a study using unconfirmed crowd-sourced reports to assess the rate of heart inflammation following Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current government included revising rules for new vaccines and discontinuing “non-essential” immunizations, she said following the vote on a online show. At the agency, Høeg has allegedly suggested excluding adolescent males from receiving Covid vaccines.

“She’s an thorough true believer who begins with her conclusions and tailors the evidence to retrofit the data in a very misleading, dishonest way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|